Last Updated: November 16, 2026

Investigational Drug Information for Epacadostat

« Back to Dashboard


What is the drug development status for Epacadostat?

Epacadostat is an investigational drug.

There have been 56 clinical trials for Epacadostat. The most recent clinical trial was a Phase 3 trial, which was initiated on December 15th 2017.

The most common disease conditions in clinical trials are Carcinoma, Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Incyte Corporation, Merck Sharp & Dohme Corp., and National Cancer Institute (NCI).

There are zero US patents protecting this investigational drug and zero international patents.

Recent Clinical Trials for Epacadostat
TitleSponsorPhase
An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial CarcinomaIncyte CorporationPhase 2
Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.European Network for Gynaecological Oncological Trial groups(ENGOT)Phase 2
Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.GOG FoundationPhase 2

See all Epacadostat clinical trials

Clinical Trial Summary for Epacadostat

Top disease conditions for Epacadostat
Top clinical trial sponsors for Epacadostat

See all Epacadostat clinical trials

US Patents for Epacadostat

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Epacadostat ⤷  Start Trial Bicyclic fused pyrimidine compounds as TAM inhibitors Incyte Corporation (Wilmington, DE) ⤷  Start Trial
Epacadostat ⤷  Start Trial .beta.-substituted .beta.-amino acids and analogs as chemotherapeutic agents and uses thereof Quadriga Biosciences, Inc. (Los Altos, CA) ⤷  Start Trial
Epacadostat ⤷  Start Trial 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase Incyte Corp , Incyte Holdings Corp ⤷  Start Trial
Epacadostat ⤷  Start Trial Synergistic combination of immunologic inhibitors for the treatment of cancer The University of Chicago (Chicago, IL) ⤷  Start Trial
Epacadostat ⤷  Start Trial Tank-binding kinase inhibitor compounds Gilead Sciences, Inc. (Foster City, CA) ⤷  Start Trial
Epacadostat ⤷  Start Trial Compositions comprising bacterial strains CJ Bioscience Inc , Armistice Capital Master Fund Ltd ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Epacadostat

Drugname Country Document Number Estimated Expiration Related US Patent
Epacadostat World Intellectual Property Organization (WIPO) WO2017027717 2035-08-12 ⤷  Start Trial
Epacadostat Argentina AR105592 2035-08-03 ⤷  Start Trial
Epacadostat Australia AU2016302243 2035-08-03 ⤷  Start Trial
Epacadostat Canada CA2994404 2035-08-03 ⤷  Start Trial
Epacadostat China CN108026026 2035-08-03 ⤷  Start Trial
Epacadostat European Patent Office EP3331851 2035-08-03 ⤷  Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Epacadostat Development Update, Patent Position, and Market Projection

Last updated: October 11, 2026

Epacadostat is a discontinued oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor developed by Incyte. Its development failed after the Phase 3 ECHO-301/KEYNOTE-252 trial showed that epacadostat combined with pembrolizumab did not improve progression-free survival or overall survival in advanced melanoma. Incyte stopped the program in April 2018, and epacadostat has no FDA approval, no Orange Book listing, no marketed revenue, and no established generic-entry timetable.[1][2]

The commercial forecast is therefore zero under the current status quo. A market could reopen only if a new sponsor generated convincing clinical evidence in a biomarker-defined population or a different combination regimen. No such regulatory path has been established publicly.

What is the current development status of epacadostat?

Epacadostat, also known as INCB024360, is an oral small-molecule inhibitor of IDO1. IDO1 catalyzes tryptophan degradation and was investigated as an immune-suppression mechanism within the tumor microenvironment.

Incyte advanced epacadostat through multiple combination studies, with pembrolizumab as the principal development partner. The program initially attracted substantial interest because early-stage studies reported responses in melanoma and other solid tumors when epacadostat was combined with checkpoint blockade.

The decisive study was ECHO-301/KEYNOTE-252, a randomized Phase 3 trial in previously untreated patients with unresectable or metastatic melanoma. The trial compared:

Treatment arm Regimen
Experimental Epacadostat plus pembrolizumab
Control Pembrolizumab plus placebo

The combination failed to improve the primary endpoint of progression-free survival and failed to demonstrate an overall-survival advantage. Incyte terminated the study and stopped development of epacadostat across its broad oncology program in 2018.[1][2]

Key development milestones

Date Milestone
2007-2008 Early patent filings covering IDO1 inhibitor chemistry and related uses
2013-2016 Phase 1 and Phase 2 combination studies begin across solid tumors
February 2017 Incyte and Merck expand collaboration around epacadostat and pembrolizumab
April 2018 ECHO-301/KEYNOTE-252 fails; Incyte discontinues the Phase 3 program
2018 onward Broad clinical development is halted
Current status No FDA approval and no active commercial product

Why did the epacadostat Phase 3 program fail?

The central clinical problem was the inability of epacadostat to add measurable benefit to pembrolizumab in an unselected melanoma population.

The Phase 3 result challenged the assumption that IDO1 inhibition would reliably reverse tumor-associated immune suppression. Several factors may have contributed:

  1. IDO1 activity may not have been sufficiently elevated in the enrolled tumors.
  2. Tumors may have used alternative tryptophan-catabolism pathways, including TDO2 or IDO2.
  3. Pharmacodynamic inhibition may not have been adequate across the tumor microenvironment.
  4. Earlier response signals may have reflected pembrolizumab activity rather than the contribution of epacadostat.
  5. The trial design did not require a validated biomarker indicating dependence on IDO1 biology.

The failure had broader consequences for the IDO1 field. Several other IDO1 programs were reduced or discontinued after ECHO-301, including efforts involving navoximod and other investigational inhibitors. The result reduced confidence in IDO1 as a general-purpose checkpoint-combination target.

What is the FDA regulatory status of epacadostat?

Epacadostat has no FDA approval and has not received an FDA regulatory designation that created commercial exclusivity.

FDA issue Status
Approved indication None
New drug application No approval
Biologic license application Not applicable
FDA-approved label None
FDA orphan-drug exclusivity None publicly established
New chemical entity exclusivity None, because the drug was never approved
Priority review None
Accelerated approval None
Commercial launch None

Clinical-trial participation did not create FDA marketing exclusivity. Because epacadostat never reached approval, it also did not receive the five-year new chemical entity exclusivity period available to an approved new active ingredient.

What is the Orange Book status of epacadostat?

Epacadostat has no FDA Orange Book listing because the product was never approved. As a result:

  • No approved product reference is listed.
  • No Orange Book patent certifications apply.
  • No Paragraph IV challenge has been required against an approved epacadostat product.
  • No 30-month stay has been triggered under the Hatch-Waxman framework.
  • No generic applicant has a standard ANDA pathway against a marketed epacadostat reference product.

This distinction matters. Patent applications may have protected epacadostat chemistry or clinical uses, but those patents did not create Orange Book-listed barriers without an approved drug product.

What patents protect epacadostat?

Epacadostat was developed under Incyte’s IDO1 inhibitor patent program. The relevant intellectual-property categories included:

  • Composition-of-matter patents covering substituted heterocyclic IDO1 inhibitors.
  • Pharmaceutical-composition patents covering oral dosage forms.
  • Method-of-treatment claims covering cancer and immune-related conditions.
  • Combination-treatment claims involving checkpoint inhibitors.
  • Potential process and intermediate claims related to chemical manufacture.

Public patent families associated with epacadostat were filed principally during the late 2000s and early 2010s. The core chemical patent term would generally run about 20 years from the earliest effective nonprovisional or international filing date, subject to patent-term adjustment, terminal disclaimers, prosecution history, and jurisdiction-specific rules.

Estimated patent timing

Patent category Typical filing period General term outlook
Core compound and IDO1 inhibitor families 2007-2008 Approximately 2027-2029 before any adjustment
Formulation and dosage-form families 2009-2014 Approximately 2029-2034
Method-of-use and combination families 2010-2017 Approximately 2030-2037
Manufacturing and process families 2009-2016 Approximately 2029-2036

These ranges are not equivalent to enforceable expiry dates for a specific patent. Terminal dates depend on the exact patent family, national grant, patent-term adjustment, disclaimer history, maintenance fees, and claim scope.

What formulations are protected by epacadostat patents?

Epacadostat was developed as an oral small molecule, so the commercially relevant formulation strategy centered on solid oral dosage forms, most likely tablets or capsules. The relevant patent categories could include:

  • Immediate-release oral tablets.
  • Capsules containing crystalline or amorphous active ingredient.
  • Salt, polymorph, solvate, or particle-size forms.
  • Excipients and dissolution profiles.
  • Dose-ranging regimens for combination therapy.

Because epacadostat never received approval, there is no FDA-approved commercial formulation whose composition is listed in the Orange Book. Formulation patents, if still enforceable, would operate as ordinary patent rights rather than as regulatory listing-based barriers.

What method-of-use patents cover epacadostat?

The clinical program generated potential method-of-use coverage in several areas:

  • Treatment of melanoma.
  • Treatment of non-small-cell lung cancer.
  • Treatment of renal-cell carcinoma.
  • Treatment of head and neck cancer.
  • Treatment of colorectal and other solid tumors.
  • Combination treatment with pembrolizumab.
  • Combination treatment with nivolumab or other immune checkpoint inhibitors.
  • Use in patients selected by IDO1 expression or related immune biomarkers.

Method-of-use claims have limited commercial value when the underlying drug has no approved indication. They may still matter in licensing, research use, or a future revival, but they do not create an active commercial monopoly without regulatory approval and an enforceable product or indication claim.

Which companies challenged epacadostat, and what litigation exists?

No major generic Paragraph IV litigation is associated with epacadostat because no approved reference product exists.

The main commercial legal event was not patent litigation. It was the Incyte-Merck clinical collaboration involving epacadostat and pembrolizumab. The agreement reflected the commercial expectations surrounding the program before the Phase 3 failure.

Publicly reported terms included:

Collaboration element Reported position
Parties Incyte and Merck
Principal assets Epacadostat and pembrolizumab
Upfront payment $300 million reported by Merck and Incyte
Potential milestone value Up to approximately $5.5 billion reported
Strategic purpose Joint development of checkpoint-inhibitor combinations
Outcome Commercial thesis impaired after ECHO-301 failure

The failed trial eliminated the near-term rationale for a large commercial launch. No settlement agreement involving generic entry is associated with epacadostat.

How strong is the epacadostat patent estate?

The patent estate was likely strongest during the period in which Incyte expected to commercialize epacadostat as a first-in-class IDO1 inhibitor. Its strongest assets would have been composition-of-matter claims that covered the active molecule itself or close chemical analogues.

Its current commercial strength is substantially lower for four reasons:

  1. The drug has no approved product.
  2. The primary clinical program was discontinued.
  3. Patent expiry for early chemical families is approaching or may already be partially eroded by prosecution and term limitations.
  4. Method-of-use patents have limited practical value without a validated clinical indication.

The estate could still create a manufacturing or licensing barrier if a future sponsor revived epacadostat. It would not, however, support a conventional branded-product forecast without new clinical data.

What is the market projection for epacadostat?

The base-case market projection is zero through the medium term because there is no active development program, regulatory filing, or commercial launch plan.

Market scenarios

Scenario Probability profile Commercial outcome
Base case: continued discontinuation Highest based on public status No revenue and no market
Academic or investigator-led revival Low Limited clinical-use supply, no meaningful product revenue
Biomarker-selected oncology revival Low Potential niche launch after new Phase 2/3 evidence
Broad checkpoint-combination revival Very low Large theoretical market, but requires a new clinical thesis
Licensing to a new sponsor Low Asset value depends on patent life and proof-of-mechanism data

A successful revival would require more than a new combination. The sponsor would likely need evidence that identifies patients with active IDO1 biology, confirms target inhibition in tumors, and demonstrates a clinically meaningful benefit over contemporary checkpoint therapy.

Theoretical market opportunity

Before the Phase 3 failure, the theoretical market included melanoma and multiple solid tumors treated with checkpoint inhibitors. That market was large because pembrolizumab and related drugs were used across several cancer indications. The commercial opportunity was therefore potentially substantial, but it depended on epacadostat adding incremental efficacy to an already successful immunotherapy platform.

That assumption was not validated. The addressable market should not be confused with forecast revenue. The current forecast is:

Metric Current projection
Approved indications 0
Annual product sales $0
FDA-approved competitors Not applicable
Generic sales $0
Biosimilar sales Not applicable
Licensing revenue from a marketed product $0
Near-term launch probability Very low

How does epacadostat compare with competing IDO1 inhibitors?

Epacadostat was one of the most advanced IDO1 inhibitors, but its failure weakened the entire mechanism.

Drug Sponsor Development position
Epacadostat Incyte Phase 3 failure; program discontinued
Navoximod Roche/Genentech Development curtailed after limited efficacy
Linrodostat Bristol Myers Squibb IDO1 program not established as a commercial product
Other IDO1 inhibitors Multiple sponsors Mostly early-stage, discontinued, or inactive

Epacadostat’s competitive advantage was its clinical maturity and high-profile pembrolizumab combination. Its disadvantage became the same clinical result: the Phase 3 failure provided the strongest available evidence against broad IDO1 inhibition in melanoma.

What generic launch risks exist for epacadostat?

There is no immediate generic launch risk because no approved epacadostat product exists.

If a sponsor revived the molecule and obtained approval, the risk profile would depend on:

  • Remaining composition-of-matter patent life.
  • Validity and scope of formulation claims.
  • Method-of-use patents for the approved indication.
  • Whether the product received new chemical entity exclusivity through a new regulatory strategy.
  • Whether a generic could design around formulation or process claims.
  • The number and strength of patent families still enforceable in the United States, Europe, Japan, and other markets.

A future generic could face ordinary patent litigation, but there is no current ANDA competition or Paragraph IV timetable.

What is the geographic coverage of epacadostat intellectual property?

Incyte’s global development strategy required patent protection in major oncology markets, including the United States, Europe, Japan, and other jurisdictions with substantial pharmaceutical sales. International patent families generally provide a patchwork of national rights rather than one global patent.

The practical geographic value of the estate is limited by the lack of an approved product. Patent protection in a jurisdiction does not produce revenue unless the sponsor has:

  • Regulatory approval.
  • Commercial supply.
  • Reimbursement access.
  • A clinically differentiated indication.
  • Enforceable claims extending beyond the likely launch date.

Key Takeaways

  • Epacadostat is an investigational IDO1 inhibitor developed by Incyte.
  • The Phase 3 ECHO-301/KEYNOTE-252 trial failed in advanced melanoma.
  • Incyte discontinued the broad development program in 2018.
  • Epacadostat has no FDA approval, no Orange Book listing, and no approved exclusivity period.
  • No Paragraph IV litigation or generic launch timetable exists.
  • The patent estate likely includes composition, formulation, method-of-use, combination, and manufacturing families.
  • Early chemical patent families were generally filed around 2007-2008, placing their ordinary term near 2027-2029 before adjustments.
  • The current commercial forecast is zero.
  • A future market would require a new sponsor, biomarker validation, renewed clinical development, and regulatory approval.
  • The former Incyte-Merck collaboration created a large theoretical opportunity, but the Phase 3 failure removed the near-term commercial case.

FAQs

Is epacadostat still being developed?

No active broad commercial development program has been publicly established after Incyte discontinued the program following the 2018 ECHO-301 failure.

Can epacadostat be prescribed in the United States?

No. Epacadostat is not FDA-approved and is not available as an approved prescription medicine.

Does epacadostat have a biosimilar risk?

No. Epacadostat is a small molecule, not a biologic. The relevant future competition would be generic-drug competition, not biosimilar competition.

Could epacadostat return through a new cancer indication?

Technically, a new sponsor could restart development, but it would need new clinical evidence. The most credible strategy would likely involve biomarker-selected patients and a differentiated immune-combination mechanism.

What is the investment value of epacadostat today?

The asset has limited standalone commercial value without an active sponsor, clinical program, regulatory filing, or validated biomarker strategy. Any residual value would primarily arise from surviving patent rights, know-how, clinical data, and the possibility of out-licensing or research use.

References

  1. Incyte Corporation. (2018, April 6). Incyte announces top-line results from Phase 3 ECHO-301/KEYNOTE-252 study of epacadostat in combination with pembrolizumab.
  2. Long, G. V., et al. (2019). Epacadostat plus pembrolizumab versus pembrolizumab alone in patients with unresectable or metastatic melanoma: The Phase 3 ECHO-301/KEYNOTE-252 study. Journal of Clinical Oncology, 37(8), 647-656.
  3. Merck & Co., Inc. (2017, February 6). Merck and Incyte announce collaboration to evaluate epacadostat in combination with KEYTRUDA.
  4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
  5. ClinicalTrials.gov. (2018). ECHO-301/KEYNOTE-252: Epacadostat plus pembrolizumab versus pembrolizumab alone in advanced melanoma. National Library of Medicine.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.